Liqin Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Liqin Zhu has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Fang Qi
Tianjin Med Univ, Pharmaceut Coll, Tianjin, Peoples R China
7 shared publicationsGaoqi Xu
Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Zhejiang, China
7 shared publicationsNa Li
Pharmaceutical College, Tianjin Medical University, Tianjin, China
7 shared publicationsLu Chen
Tianjin Med Univ, Pharmaceut Coll, Tianjin, Peoples R China
6 shared publicationsMengxue Li
Pharmaceutical College Tianjin Medical University, Tianjin, China
6 shared publicationsTingyue Ge
C Department of Pharmacology , Tianjin Medical University , Tianjin , China
6 shared publications
Latest Publications
- Open Access
- 31 January 2024
- Published by Wiley
Population pharmacokinetics and covariate analysis of anlotinib in patients with malignant tumors
Aims Anlotinib is a novel oral tyrosine kinase inhibitor that targets VEGFR-2, VEGFR -3, FGFR1-4, PDGFR-α, PDGFR-β, c-Kit, and Ret. This study aimed to develop a population pharmacokinetic model of anlotinib in patients with malignant tumors and identify various covariates that might affect its pharmacokinetic parameters. Methods 407 plasma concentrations from 16 patients were analyzed to establish a population pharmacokinetic model using the nonlinear mixed-effects model method. All patients were administered anlotinib (12 mg) orally, as a single drug therapy. The potential influence of demographic, hepatic, and renal function data was investigated using automated stepwise covariate model. The final model was evaluated using diagnostic goodness-of-fit plots, bootstrap, and visual predictive check methods. Results A one-compartment model with first-order absorption and elimination adequately described anlotinib pharmacokinetics. The population estimates of apparent total plasma clearance (CL/F) was 9.26 L/h (29.20% IIV), apparent volume of distribution (V/F) was 2010 L (29.20 IIV), and absorption rate constant (Ka) was 0.64 h-1 (56.70% IIV). Total cholesterol (TC) was identified as a covariate affecting CL/F, while alkaline phosphatase (ALP) was found to be statistically significant for V/F. Conclusion The population pharmacokinetic model adequately described the pharmacokinetics of anlotinib in patients with malignant tumors. TC and ALP might have a slight effect on the pharmacokinetic profile of anlotinib.
- 31 January 2024
- Published by Wiley
Open AccessPopulation pharmacokinetics and covariate analysis of anlotinib in patients with malignant tumors
Aims Anlotinib is a novel oral tyrosine kinase inhibitor that targets VEGFR-2, VEGFR -3, FGFR1-4, PDGFR-α, PDGFR-β, c-Kit, and Ret. This study aimed to develop a population pharmacokinetic model of anlotinib in patients with malignant tumors and identify various covariates that might affect its pharmacokinetic parameters. Methods 407 plasma concentrations from 16 patients were analyzed to establish a population pharmacokinetic model using the nonlinear mixed-effects model method. All patients were administered anlotinib (12 mg) orally, as a single drug therapy. The potential influence of demographic, hepatic, and renal function data was investigated using automated stepwise covariate model. The final model was evaluated using diagnostic goodness-of-fit plots, bootstrap, and visual predictive check methods. Results A one-compartment model with first-order absorption and elimination adequately described anlotinib pharmacokinetics. The population estimates of apparent total plasma clearance (CL/F) was 9.26 L/h (29.20% IIV), apparent volume of distribution (V/F) was 2010 L (29.20 IIV), and absorption rate constant (Ka) was 0.64 h-1 (56.70% IIV). Total cholesterol (TC) was identified as a covariate affecting CL/F, while alkaline phosphatase (ALP) was found to be statistically significant for V/F. Conclusion The population pharmacokinetic model adequately described the pharmacokinetics of anlotinib in patients with malignant tumors. TC and ALP might have a slight effect on the pharmacokinetic profile of anlotinib.
- Open Access
- 11 February 2022
- Published by Wiley
Evaluating Linezolid Dose Based on Renal Function and Body Weight against Methicillin-Resistant Staphylococcus aureus (MRSA) by Monte Carlo Simulations
Objective: To assess whether dose adjustments of linezolid were needed based on renal function and body weight against methicillin-resistant Staphylococcus aureus (MRSA) infections. Methods: Monte Carlo simulations (MCSs) were conducted to simulate pharmacokinetic/pharmacodynamic (PKPD) model. Area under the concentration time curve (AUC)/ minimum inhibitory concentration (MIC) ratio and percentage of time above the MIC (%T>MIC) were regarded as PKPD targets. The probability of target attainment (PTA) and cumulative fractions of response (CFR) were calculated to assess the efficacy. Regarding safety, trough plasma concentration (Cmin) > 8 mg/L was used to target for toxicity. Results: Using AUC /MIC > 100 as the parameter, the CFR of linezolid at the standard dose [600 mg every 12 h (q12h)] were 57.01%, 93.22% and 99.93% in patients with normal renal function, patients with renal dysfunction and low body weight patients with renal dysfunction, respectively. Using 100%T > MIC as the parameter, all the CFR of three population groups were more than 90% at the standard dose. The percentages of Cmin > 8 mg/L at the standard dose of linezolid were 24.16%, 53.24% and 90.10% in three population groups on day 7. Conclusions: The risk of thrombocytopenia of linezolid was extremely high in low body weight patients with renal impairment when receiving standard linezolid dose. 600 mg q12h might be effective and safe against MRSA infection in patients with normal renal function, while 450mg q12h and 300mg q12h in patients with renal dysfunction and low body weight patients with renal dysfunction, respectively.
- 11 February 2022
- Published by Wiley
Open AccessEvaluating Linezolid Dose Based on Renal Function and Body Weight against Methicillin-Resistant Staphylococcus aureus (MRSA) by Monte Carlo Simulations
Objective: To assess whether dose adjustments of linezolid were needed based on renal function and body weight against methicillin-resistant Staphylococcus aureus (MRSA) infections. Methods: Monte Carlo simulations (MCSs) were conducted to simulate pharmacokinetic/pharmacodynamic (PKPD) model. Area under the concentration time curve (AUC)/ minimum inhibitory concentration (MIC) ratio and percentage of time above the MIC (%T>MIC) were regarded as PKPD targets. The probability of target attainment (PTA) and cumulative fractions of response (CFR) were calculated to assess the efficacy. Regarding safety, trough plasma concentration (Cmin) > 8 mg/L was used to target for toxicity. Results: Using AUC /MIC > 100 as the parameter, the CFR of linezolid at the standard dose [600 mg every 12 h (q12h)] were 57.01%, 93.22% and 99.93% in patients with normal renal function, patients with renal dysfunction and low body weight patients with renal dysfunction, respectively. Using 100%T > MIC as the parameter, all the CFR of three population groups were more than 90% at the standard dose. The percentages of Cmin > 8 mg/L at the standard dose of linezolid were 24.16%, 53.24% and 90.10% in three population groups on day 7. Conclusions: The risk of thrombocytopenia of linezolid was extremely high in low body weight patients with renal impairment when receiving standard linezolid dose. 600 mg q12h might be effective and safe against MRSA infection in patients with normal renal function, while 450mg q12h and 300mg q12h in patients with renal dysfunction and low body weight patients with renal dysfunction, respectively.
- 2 July 2021
- Published by Taylor & Francis in Xenobiotica
- Vol. 51 (8) , 877-884
Drug–drug interaction comparison between tacrolimus and phenobarbital in different formulations for paediatrics and adults
To compare drug–drug interaction (DDI) between tacrolimus and different formulations of phenobarbital in paediatrics and adults.Physiologically based pharmacokinetics (PBPK) models were used to eva...
- 2 July 2021
- Published by Taylor & Francis in Xenobiotica
- Vol. 51 (8) , 877-884
Drug–drug interaction comparison between tacrolimus and phenobarbital in different formulations for paediatrics and adults
To compare drug–drug interaction (DDI) between tacrolimus and different formulations of phenobarbital in paediatrics and adults.Physiologically based pharmacokinetics (PBPK) models were used to eva...
- 1 February 2021
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 59 (02) , 156-159
Linezolid-induced thrombocytopenia in a child with a liver transplant: A case report
Objective: Linezolid-induced thrombocytopenia is rarely reported in liver transplant patients, especially in children. Case summary: We report a case of a 7-month-old liver-transplanted child who suffered from thrombocytopenia induced by linezolid. We simulated the pharmacokinetic of linezolid in a healthy adult using the physiologically based pharmacokinetic (PBPK) model and found that the liver is the most abundant organ for the distribution of linezolid. Practice implications: Linezolid has a high distribution in the liver. As a result. an increased awareness about the risk of linezolid-induced thrombocytopenia should be strengthened in patients with liver injury. Effects of ethnicity: The differences between Chinese patients and patients of other ethnicities may lead to the diverse effects of linezolid in different patients. The influence of body weight (BW) difference in pharmacokinetics (PK) of linezolid between Asian (Chinese and Japanese) and Caucasians was demonstrated in several population PK studies [1, 2. 3]. The average BW of Asians is lower than that of the Caucasian population, the clearance and apparent volume of distribution are lower than in the European population, and C-max is higher than in the Western population. Therefore. the adverse effects of linezolid at the same dose may increase in Chinese patients.
- 1 February 2021
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 59 (02) , 156-159
Linezolid-induced thrombocytopenia in a child with a liver transplant: A case report
Objective: Linezolid-induced thrombocytopenia is rarely reported in liver transplant patients, especially in children. Case summary: We report a case of a 7-month-old liver-transplanted child who suffered from thrombocytopenia induced by linezolid. We simulated the pharmacokinetic of linezolid in a healthy adult using the physiologically based pharmacokinetic (PBPK) model and found that the liver is the most abundant organ for the distribution of linezolid. Practice implications: Linezolid has a high distribution in the liver. As a result. an increased awareness about the risk of linezolid-induced thrombocytopenia should be strengthened in patients with liver injury. Effects of ethnicity: The differences between Chinese patients and patients of other ethnicities may lead to the diverse effects of linezolid in different patients. The influence of body weight (BW) difference in pharmacokinetics (PK) of linezolid between Asian (Chinese and Japanese) and Caucasians was demonstrated in several population PK studies [1, 2. 3]. The average BW of Asians is lower than that of the Caucasian population, the clearance and apparent volume of distribution are lower than in the European population, and C-max is higher than in the Western population. Therefore. the adverse effects of linezolid at the same dose may increase in Chinese patients.
- 6 August 2020
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 32 (8) , 420-428
Optimization of tigecycline dosage regimen for different infections in the patients with hepatic or renal impairment
The objective of this study was to investigate the cumulative fraction of response (CFR) of various tigecycline dosing regimens in patients with hepatic or renal impairment. Monte Carlo simulations...
- 6 August 2020
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 32 (8) , 420-428
Optimization of tigecycline dosage regimen for different infections in the patients with hepatic or renal impairment
The objective of this study was to investigate the cumulative fraction of response (CFR) of various tigecycline dosing regimens in patients with hepatic or renal impairment. Monte Carlo simulations...
- 8 April 2020
- Published by Springer Nature in Pediatric Research
- Vol. 88 (3) , 342
Possible causes for decreased susceptibility of children to coronavirus
- 8 April 2020
- Published by Springer Nature in Pediatric Research
- Vol. 88 (3) , 342
Possible causes for decreased susceptibility of children to coronavirus
- 12 March 2020
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 16 (3) , 271-274
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019
- 12 March 2020
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 16 (3) , 271-274
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019
- 11 February 2020
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (5) , 695-702
Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations
To assess the efficacy of loading dose on micafungin by simulating different dosage regimens.
- 11 February 2020
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (5) , 695-702
Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations
To assess the efficacy of loading dose on micafungin by simulating different dosage regimens.
- 22 July 2019
- Published by Taylor & Francis in Xenobiotica
- Vol. 50 (2) , 196-201
Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients
1. There are still no studies examining the relationship between body composition and tacrolimus pharmacokinetics in liver transplantation recipients. We aimed to investigate the influence of body composition on tacrolimus pharmacokinetics in liver transplantation recipients. 2. Body composition was measured in 80 patients who underwent liver transplantation at Tianjin First Central Hospital, China, between 2015 and 2018. Blood concentration of tacrolimus were collected from therapeutic drug monitoring data. Pharmacokinetic model fitting and bayesian estimation were performed using nonlinear mixed effects modeling(NONMEM)and SPSS was used to examine the effect of body composition on tacrolimus pharmacokinetics. 3. The apparent volume of distribution(V/F)and clearance(CL/F)of tacrolimus were 179L and 15.4L/h, respectively. In liver transplantation recipients with percentage body fat(PBF)≥30%, the apparent V/F of tacrolimus is lower than that in liver transplantation recipients with PBF <30% at one week after liver transplantation. 4. The new finding is important due to the severe adverse effects of tacrolimus. In clinical practice, an effective dosage adjustment of tacrolimus may need to be considered in patients with PBF ≥30% at one week after liver transplantation.
- 22 July 2019
- Published by Taylor & Francis in Xenobiotica
- Vol. 50 (2) , 196-201
Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients
1. There are still no studies examining the relationship between body composition and tacrolimus pharmacokinetics in liver transplantation recipients. We aimed to investigate the influence of body composition on tacrolimus pharmacokinetics in liver transplantation recipients. 2. Body composition was measured in 80 patients who underwent liver transplantation at Tianjin First Central Hospital, China, between 2015 and 2018. Blood concentration of tacrolimus were collected from therapeutic drug monitoring data. Pharmacokinetic model fitting and bayesian estimation were performed using nonlinear mixed effects modeling(NONMEM)and SPSS was used to examine the effect of body composition on tacrolimus pharmacokinetics. 3. The apparent volume of distribution(V/F)and clearance(CL/F)of tacrolimus were 179L and 15.4L/h, respectively. In liver transplantation recipients with percentage body fat(PBF)≥30%, the apparent V/F of tacrolimus is lower than that in liver transplantation recipients with PBF <30% at one week after liver transplantation. 4. The new finding is important due to the severe adverse effects of tacrolimus. In clinical practice, an effective dosage adjustment of tacrolimus may need to be considered in patients with PBF ≥30% at one week after liver transplantation.
- 8 July 2019
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 20 (6) , 247
The Pharmacokinetic Prediction of Cyclosporin A after Coadministration with Wuzhi Capsule
We aim to describe the influence of principal ingredients of Wuzhi capsule, schisandrin A (SIA) and schisantherin A (STA), on the pharmacokinetics of cyclosporin A (CsA) and to quantify the herb–drug...
- 8 July 2019
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 20 (6) , 247
The Pharmacokinetic Prediction of Cyclosporin A after Coadministration with Wuzhi Capsule
We aim to describe the influence of principal ingredients of Wuzhi capsule, schisandrin A (SIA) and schisantherin A (STA), on the pharmacokinetics of cyclosporin A (CsA) and to quantify the herb–drug...